Takeda in talks to buy rival Nycomed
Friday 13 May 2011
Japan's largest drug maker Takeda Pharmaceutical is in talks to buy its privately held Swiss rival Nycomed for more than $12bn (£7bn) in an attempt to extend its global reach into Europe and emerging markets.
The purchase would offer the mainly Asia and US-focused maker of drugs for diabetes and heart disease access to a lung disease drug, Daxas, just approved in the United States, and a portfolio of over-the-counter consumer products.
A Nycomed deal would be Japan's second-biggest overseas takeover according to Thomson Reuters data – after Japan Tobacco's $19bn buy of Britain's Gallagher – and would be a second major deal for Takeda after it bought the US cancer drug specialist Millennium Pharmaceuticals in 2008 for about $9bn.
Simon Calder looks at communities fighting back against the poachers
Arsenal 1 Everton 1: Substitute equalises with six minutes to go
booksGeese, gorillas, grandads... and growing up
Guide dog mauled while helping owner deliver Christmas cards
The poorest pay the price for austerity: Workers face biggest fall in living standards since Victorian era
Icon or terrorist: Nelson Mandela’s complex bond with Britain
Deadly ice storm sees US temperatures drop to -29C
10 stone five-year-old taken into care
- 1 A forgotten episode in Russian history leaves links with the Philippines
- 2 Turning up the voice of America
- 3 The man who made Femen: New film outs Victor Svyatski as the mastermind behind the protest group and its breast-baring stunts
- 4 Mass murder in the Middle East is funded by our friends the Saudis
- 5 Japan cracks down on leaks after scandal of Fukushima nuclear power plant
- < Previous
- Next >
iJobs Money & Business
£25000 - £50000 per annum + Benefits + Bonus: Harrington Starr: C++ Server Dev...
£300 - £350 per day: Harrington Starr: Leading Electronic Trading Software Ven...
£80000 - £100000 per annum + benefits + bonus: Harrington Starr: Project Manag...
£50000 - £60000 per annum + benefits + bonus: Harrington Starr: Business Analy...